All In Biotech

NDA 019865 · Legacy

Betapace

Sotalol Hydrochloride · Oral

NovelPriority reviewOrphan

Last checked: Nov 21, 2026Latest source record: Jun 15, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Oct 30, 1992

Approved uses

2

Original approval plus efficacy supplements

Registered trials

57

14 Phase 3, 9 recruiting

FAERS reports

3,865

3,025 serious, 400 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LIFE-THREATENING PROARRHYTHMIA To minimize the risk of drug-induced arrhythmia, initiate or reinitiate oral sotalol in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring. Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation. If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug. Calculate creatinine clearance to determine appropriate dosing [see Dosage and Administration ( 2.5 ) ] . WARNING: LIFE-THREATENING PROARRHYTHMIA See full prescribing information for complete boxed warning. Betapace/Betapace AF can cause life-threatening ventricular tachycardia associated with QT interval prolongation. If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug....

What it is approved for

From the label in effect Dec 16, 2024.

Betapace/Betapace AF is an antiarrhythmic indicated for: the treatment of life-threatening ventricular arrhythmias ( 1.1 ) the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) ( 1.2 ) Limitations of Use Betapace has not been shown to enhance survival in patients with life threatening ventricular arrhythmias ( 1.1 ) Avoid use in patients with minimally symptomatic or easily reversible AFIB/AFL ( 1.2 ) 1.1 Life-Threatening Ventricular Arrhythmias Betapace/Betapace AF is indicated for the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia (VT) . Limitation of Use: Betapace/Betapace AF has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias. 1.2 Delay in Recurrence of Atrial Fibrillation/Atrial Flutter (AFIB/AFL) Betapace/Betapace AF is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of AFIB/AFL) in patients with highly symptomatic AFIB/AFL who are currently in sinus rhythm. Limitation of Use: Because Betapace/Betapace AF can cause life-threatening ventricular arrhythmias, reserve its use for patients in whom AFIB/AFL is highly symptomatic. Patients with paroxysmal AFIB that is easily reversed (by Valsalva maneuver, for example) should usually not be given Betapace/Betapace AF.

Mechanism: Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. The two isomers of sotalol have similar Class III antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-blocking activity. The beta-blocking effect of sotalol is non-cardioselective, half maximal at about 80 mg/day and maximal at doses between 320 and 640 mg/day. Sotalol does not have partial agonist or membrane stabilizing activity. Although significant beta-blockade occurs at...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 1, 2001 Supplement 10 · Efficacy ReviewLabelLetter
  • Oct 30, 1992 Original approval · Type 1 - New Molecular Entity · priority review
5 products under this application
  • BETAPACE · SOTALOL HYDROCHLORIDE 80MG · TABLET, ORAL · Prescription · TE AB
  • BETAPACE · SOTALOL HYDROCHLORIDE 320MG · TABLET, ORAL · Discontinued
  • BETAPACE · SOTALOL HYDROCHLORIDE 160MG · TABLET, ORAL · Prescription · TE AB
  • BETAPACE · SOTALOL HYDROCHLORIDE 120MG · TABLET, ORAL · Prescription · TE AB
  • BETAPACE · SOTALOL HYDROCHLORIDE 240MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sotalol" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • atrial fibrillation355
  • drug ineffective220
  • dyspnoea219
  • dizziness189
  • hypotension189
  • fatigue183
  • nausea182
  • electrocardiogram qt prolonged157
  • asthenia149
  • diarrhoea142
  • bradycardia137
  • fall123

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004139
200592
2006210
2007283
200897
2009178
2010133
2011165
2012198
2013122
2014166
2015142
2016146
2017168
2018187
2019187
2020143
2021127
2022170
2023167
2024210
2025267
2026168

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Betapace (Sotalol HCl)

2024 spending

$535K

Beneficiaries

49

197 claims

Per beneficiary

$10,909

$26.84 per unit

View as table
YearSpending
2020$1,150,057
2021$892,876
2022$721,553
2023$676,553
2024$534,563

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 421 on PubMed

Sponsor: Legacy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.